Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Autor: | Hill, Brian T., Ma, Shuo, Zent, Clive S., Baran, Andrea M., Wallace, Danielle S., Advani, Anjali, Winter, Allison, Winter, Jane, Gordan, Leo, Karmali, Reem, Liesveld, Jane L., Mulford, Deborah A., Rowland, Chris, Bui, Andrew, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Friedberg, Jonathan W., Barr, Paul M. |
---|---|
Zdroj: | In Blood Advances 23 January 2024 8(2):378-387 |
Databáze: | ScienceDirect |
Externí odkaz: |